Clinical trials: HSV Infection
Recurrent Herpes Labialis
Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores
The purpose of this study is to determine if Merlin, a mixture of ethanol and glycolic acid, is safe and effective in the treatment of cold sores.
- Trial name
- NCT01985321
- Testing
- ethanol/glycolic acid solution
- Where
- 8 sites in United States
- Volunteers
- 469 people
- Sponsor
- Topical Remedy
Herpes Zoster
Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
PRIMARY OBJECTIVES Two co-primary objectives are: To demonstrate that the immunogenicity of ZOSTAVAX administered by intramuscular route (IM) is non-inferior to ZOSTAVAX administered by subcutaneous route (SC) To demonstrate that…
- Trial name
- NCT01391546
- Testing
- ZOSTAVAX
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects
Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles).
- Trial name
- NCT00434577
- Testing
- Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)
Primary objective: To demonstrate whether or not ZOSTAVAX® at minimum release specification approaching expiry potency elicits an acceptable Varicella-Zoster Virus (VZV) antibody fold rise (measured by glycoprotein Enzyme Linked…
- Trial name
- NCT00681031
- Testing
- ZOSTAVAX®
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ).
- Trial name
- NCT01827839
- Testing
- Herpes Zoster vaccine (GSK1437173A)
- Where
- 4 sites in Canada, Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Herpes Zoster Vaccine
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine.
- Trial name
- NCT02075515
- Testing
- Herpes Zoster vaccine (GSK 1437173A)
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 651 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.
- Trial name
- NCT02581410
- Testing
- GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
- Where
- 32 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age
- Trial name
- NCT02979639
- Testing
- GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
- Where
- 11 sites in United States
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as…
- Trial name
- NCT03439657
- Testing
- HZ/su vaccine GSK1437173A, Prevenar13
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
This is a study to evaluate the safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic…
- Trial name
- NCT01527383
- Testing
- V212
- Volunteers
- 354 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Drug-Drug Interaction Study: ASP2151 and Bupropion
CYP2B6 is involved in the metabolism of many drugs. So, it is important to assess in vivo the effect of ASP2151 on that enzyme to determine any possible drug interactions.
- Trial name
- NCT02369172
- Testing
- Bupropion, ASP2151
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Inflammatory Bowel Diseases, Crohn Disease
Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab
Inflammatory bowel disease (IBD) is a chronic inflammatory state of the gastrointestinal tract affecting 1.6-3.1 million people in the United States.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
- Trial name
- NCT03798691
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Wisconsin, Madison
Herpes Labialis
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent…
- Trial name
- LipP1 (NCT02871492)
- Testing
- Pritelivir 5% w/w ointment, Zovirax® cream
- Where
- 10 sites in United States
- Volunteers
- 362 people
- Sponsor
- AiCuris Anti-infective Cures AG
Herpes Simplex
Phase III Study of ASP2151 in Herpes Simplex Patients
To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.
- Trial name
- NCT01959295
- Testing
- ASP2151
- Where
- 3 sites in Japan
- Volunteers
- 468 people
- Sponsor
- Maruho Co., Ltd.
Herpes Labialis
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
- Trial name
- NCT01574612
- Testing
- acyclovir/hydrocortisone cream
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Meda Pharmaceuticals
HIV Infections, HSV-2 Genital Herpes
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013…
- Trial name
- NCT00740584
- Testing
- 3% SPL7013 Gel (VivaGel)
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
Oral Herpes Simplex
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection
The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.
- Trial name
- NCT01308424
- Testing
- BTL TML HSV
- Where
- 4 sites in United States
- Volunteers
- 171 people
- Sponsor
- Beech Tree Labs, Inc.
Shingles
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.
- Trial name
- NCT00534248
- Testing
- Zoster Vaccine, Live (Zostavax™)
- Volunteers
- 22,439 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Varicella-zoster Vaccine
Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)
This study was conducted to obtain safety and immunogenicity data after a booster dose of Zoster Vaccine, Live administered ≥10 years following an initial dose.
- Trial name
- NCT01245751
- Testing
- Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC